DeutschNewstral
Article
jdsupra.com on 2018-04-02 22:17
New Use Patent for Janssen’s REMICADE valid and infringed by Hospira’s biosimilar INFLECTRA
Related news
- Federal Court finds Janssen’s macitentan combination therapy patent validjdsupra.com
- Federal Court finds silodosin formulation patent valid but not infringedjdsupra.com
- LUMIGAN RC formulation patent found valid and infringedjdsupra.com
- Federal Court decision regarding glatiramer acetate finds one patent obvious and another valid and infringedjdsupra.com
- Federal Court reinstates decision that REMICADE new use patent is valid and infringedjdsupra.com
- Janssen and Celltrion: Remicade Biosimilar Patent Dancejdsupra.com
- Remicade Biosimilar Closer To Approval, But Patent Dance Goes Onjdsupra.com
- Janssen’s abiraterone acetate and prednisone combination therapy patent found invalidjdsupra.com
- Dexlansoprazole formulation patent invalid and not infringed by Apotexjdsupra.com
Court Says Pfizer's Biosimilar of J&J's Remicade Doesn't Infringe Patentwsj.com- Janssen Seeks Injunction Against Remicade Biosimilar Based On Cell Culture Patentjdsupra.com
- Celltrion's Proposed REMICADE® Biosimilar Recommended for Approvaljdsupra.com
- FDA Approves Inflectra - Celltrion's REMICADE® Biosimilarjdsupra.com
- No Section 8 Liability for Valid and Infringed Patent in NEXIUM Proceedingjdsupra.com
- Federal Court finds formulation patent relating to ACTONEL DR valid but not infringedjdsupra.com
- Merck’s JANUVIA crystalline monohydrate DHP salt patent found validjdsupra.com
Patent for J&J's Remicade invalidatedThe Salt Lake Tribune- J&J and Pfizer Settle Remicade Biosimilar Antitrust Suitjdsupra.com
- FDA Accepts Samsung Bioepis’s BLA for Remicade® Biosimilarjdsupra.com
FDA approves biosimilar competition for J&J's Remicade drugbizjournals.com